Description: Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company is developing Probuphine for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment; and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company's ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson's disease. It is also developing Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.
Home Page: www.titanpharm.com
TTNP Technical Analysis
400 Oyster Point Boulevard
South San Francisco,
CA
94080-1958
United States
Phone:
650 244 4990
Officers
| Name | Title |
|---|---|
| Dr. Katherine L. Beebe-DeVarney Ph.D. | Pres, COO & Director |
| Dr. Marc Rubin M.D. | Exec. Director |
| Mr. David Elliot Lazar | Principal Exec. Officer, Principal Financial Officer, CEO & Interim Chairman |
| Mr. Mike Fritz | National Sales Director |
| Jennifer Kiernan | Exec. Assistant to CEO & Investor Communications Coordinator |
| Joe Schrei | Exec. Director of Commercial Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.0385 |
| Price-to-Sales TTM: | 22.8021 |
| IPO Date: | 1996-01-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |